Use of inhibitors of PI3K-C2A for the treatment of apoptos i s-related disorders

Details for Australian Patent Application No. 2006312279 (hide)

Owner Novartis AG

Inventors Murphy, Leon; Mac Keigan, Jeff; Triantafellow, Ellen; Finan, Peter

Agent Davies Collison Cave

Pub. Number AU-A-2006312279

PCT Pub. Number WO2007/055773

Priority 60/711,533 26.08.05 US

Filing date 24 August 2006

Wipo publication date 18 May 2007

International Classifications

A61K 31/70 (2006.01) - Carbohydrates

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

C12Q 1/00 (2006.01) Measuring or testing processes involving enzymes or micro-organisms

Event Publications

13 March 2008 PCT application entered the National Phase

  PCT publication WO2007/055773 Priority application(s): WO2007/055773

16 December 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006312284-System and method for routing information

2006312273-Molecularly imprinted polymer ion exchange resins